Renata PLC announcements
340 Dhaka Stock Exchange announcements for Renata PLC (RENATA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2026 (16).
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 08, 2026 at 2:30 PM to consider, among others, Un-Audited Financial Statements for the First Quarter (Q1) period ended September 30, 2026.
- Dividend Declaration
The Board of Directors has recommended 55% Cash Dividend for the year ended June 30, 2026. Date of AGM: 19.12.2026, Time: 11:30 AM, Venue: Digital Platform. Record Date: 15.11.2026. The Company has also reported Consolidated EPS of Tk. 31.76, Consolidated NAV per share of Tk. 329.19 and Consolidated NOCFPS of Tk. 49.88 for the year ended 30-Jun-2026 as against Consolidated EPS of Tk. 19.36, Consolidated NAV per share of Tk. 305.49 and Consolidated NOCFPS of Tk. 41.16 for the year ended 30-Jun-2025.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (18.10.2026) following its corporate declaration.
- Update of Information
The Company has requested the shareholders to check and update their BOID's e-mail address, mobile number and Bank A/c details along with Routing Number to get Dividend online through BEFTN system.
- Change of Board Meeting Time under LR 19(1)
The Company has further informed that, the Board meeting under LR 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on October 17, 2026 at 2:30 PM instead of 12:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 17, 2026 at 12:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.
- Credit Rating Result
Alpha Credit Rating PLC. has assigned Surveillance rating of the Company as "AAA" in the long term and "ST-1" in the short term along with Stable outlook based on audited financial statement for the year ended 30 June of FY 2024-2025, unaudited financial statement for the 3rd quarter ended March 2026 and relevant qualitative information till 14 September, 2026.
- Company exports first Therapeutics consignment to Portugal
The company has informed that it has expanded its presence in the European market by dispatching its first consignment of therapeutics to Portugal. The initial launch includes Amantadine 100 mg capsules, manufactured at EU-GMP-approved Rajendrapur General Facility, alongside Fludrocortisone 0.1 mg tablets & Cabergoline 0.5 mg tablets, produced at EU-GMP-approved Mirpur Potent Facility. This entry into Portugal represents a significant step in Renata's ongoing international expansion strategy across Europe.
- Renata PLC Secures European approval for Thyrox (Levothyroxine)
The company has informed that it has received approval for its Levothyroxine Sodium tablets under the EU Decentralised Procedure (DCP) in Ireland, Germany, Italy, Poland, Portugal and Malta. The product will be manufactured at Renata's EU GMP-approved potent product facility. Renata PLC intends to support safe and reliable access to Levothyroxine in the newly approved EU markets.
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 6.81 for January-March 2026 as against Tk. 5.12 for January-March 2025; Consolidated EPS was Tk. 20.39 for July 2025-March 2026 as against Tk. 15.95 for July 2024-March 2025. Consolidated NOCFPS was Tk. 22.40 for July 2025-March 2026 as against Tk. 21.76 for July 2024-March 2025. Consolidated NAV per share was Tk. 320.02 as on March 31, 2026, and Tk. 305.49 as on June 30, 2025.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 2:30 PM to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 7.11 for October-December 2025 as against Tk. 5.64 for October-December 2024; Consolidated EPS was Tk. 13.58 for July-December 2025 as against Tk. 10.83 for July-December 2024. Consolidated NOCFPS was Tk. 12.87 for July-December 2025 as against Tk. 3.60 for July-December 2024. Consolidated NAV per share was Tk. 313.48 as on December 31, 2025 and Tk. 305.49 as on June 30, 2025. (cont.1) (Cont. News of RENATA): NOCFPS: The improvement was primarily attributable to strong growth in operating profit. Enhanced working capital management, reflected in lower cash tied up with inventories and trade and other receivables compared to the six-month period ended 31 December 2024, also contributed to the increase. In addition, higher depreciation and amortisation, as non-cash adjustments to profit before tax, further supported the growth in NOCF. (end) (Cont. News of RENATA): Reasons for deviations: EPS: EPS increased primarily due to strong growth in operating profit and reduction in net finance cost driven by capital restructuring initiative. This was partially offset by higher income tax expense. (cont.2)
- UK Marketing Authorization for Esomeprazole MUPS
The company has informed that it has received Marketing Authorization (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom, for Esomeprazole 20 mg and 40 mg Gastro-Resistant Tablets. This approval allows the product to be marketed in the UK, a highly regulated pharmaceutical market.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2026 at 3:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.
- Company secures Turkish regulatory approval for flagship facility
The company has informed that they have received regulatory approval from the Turkish Medicines and Medical Devices Agency for its Rajendrapur General Facility, qualifying the site to register and supply oral solid dosage pharmaceutical products (tablets and capsules) in Turkey. Turkey represents a strategically important market for Renata, positioned at the intersection of Europe and the Middle East. (cont.) (Cont. News of RENATA): This approval further strengthens the Company's international footprint and complements the facility's existing approvals from other stringent regulatory authorities, including EU GMP and US FDA, reaffirming Renata's commitment to global quality standards. The Company also anticipates regulatory approval of Amantadine in Turkey within the next year, which is expected to further support Renata's commercial expansion in the region. (end)
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.